In the present paper, we evaluated the potential therapeutic effects of combining Gemcitabine with a novel single chain bispecific antibody (scDb-hERG1-β1) which targets the cancer-specific hERG1/β1 integrin complex. This evidence concerns the gene KCNH2 and cancer.